Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2013 Feb 27

PMID 23439547

Citations 37

Authors

Elisa Ridolfi

Chiara Fenoglio

Claudia Cantoni

Alberto Calvi

Milena De Riz

Anna Pietroboni

Chiara Villa

Maria Serpente

Rossana Bonsi

Marco Vercellino

Paola Cavalla

Daniela Galimberti

Elio Scarpini

Affiliations

Soon will be listed here.

Abstract

Evidence underlines the importance of microRNAs (miRNAs) in the pathogenesis of multiple sclerosis (MS). Based on the fact that miRNAs are present in human biological fluids, we previously showed that miR-223, miR-23a and miR-15b levels were downregulated in the sera of MS patients versus controls. Here, the expression levels of these candidate miRNAs were determined in peripheral blood mononuclear cells (PBMCs) and the serum of MS patients, in addition to three genotyped single nucleotide polymorphisms (SNPs). Mapping in the genomic regions of miR-223, miR-23a and miR-15b genes, 399 cases and 420 controls were tested. Expression levels of miR-223 and miR-23a were altered in PBMCs from MS patients versus controls. Conversely, there were no differences in the expression levels of miR-15b. A significantly decreased genotypic frequency of miR-223 rs1044165 T/T genotype was observed in MS patients. Moreover, the allelic frequency of miR-23a rs3745453 C allele was significantly increased in patients versus controls. In contrast, there were no differences in the distribution of miR-15b SNP. In conclusion, our results suggest that miR-223 and miR-23a could play a role in the pathogenesis of MS. Moreover, miR-223 rs1044165 polymorphism likely acts as a protective factor, while miR-23a rs3745453 variant seems to act as a risk factor for MS.

Citing Articles

Mitochondrial microRNAs: Key Drivers in Unraveling Neurodegenerative Diseases.

Yashooa R, Duranti E, Conconi D, Lavitrano M, Mustafa S, Villa C Int J Mol Sci. 2025; 26(2).

PMID: 39859339 PMC: 11766038. DOI: 10.3390/ijms26020626.

Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma.

Suvarnapathaki S, Serrano-Farias A, Dudley J, Bettegowda C, Rincon-Torroella J Life (Basel). 2024; 14(10).

PMID: 39459612 PMC: 11509808. DOI: 10.3390/life14101312.

Dysregulation of miR-223, miR-146a, and miR-193a Expression Profile in Acute and Chronic Phases of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice.

Gharibi S, Moghimi B, Mahmoudi M, Shahvazian E, Yazd E, Yadegari M Cells. 2024; 13(17.

PMID: 39273069 PMC: 11393975. DOI: 10.3390/cells13171499.

Potential biomarkers for multiple sclerosis stage from targeted proteomics and microRNA sequencing.

Tan I, Modderman R, Stachurska A, Almeida R, de Vries R, Heersema D Brain Commun. 2024; 6(4):fcae209.

PMID: 38978729 PMC: 11229703. DOI: 10.1093/braincomms/fcae209.

Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis.

Gosetti di Sturmeck T, Malimpensa L, Ferrazzano G, Belvisi D, Leodori G, Lembo F Int J Mol Sci. 2024; 25(12).

PMID: 38928049 PMC: 11203572. DOI: 10.3390/ijms25126342.

References

Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Decard B . Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology. 2012; 79(22):2166-70. DOI: 10.1212/WNL.0b013e3182759621. View

Sarchielli P, Di Filippo M, Ercolani M, Chiasserini D, Mattioni A, Bonucci M . Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett. 2008; 435(3):223-8. DOI: 10.1016/j.neulet.2008.02.040. View

Miller A . Multiple sclerosis: where will we be in 2020?. Mt Sinai J Med. 2011; 78(2):268-79. DOI: 10.1002/msj.20242. View

Fenoglio C, Ridolfi E, Galimberti D, Scarpini E . MicroRNAs as active players in the pathogenesis of multiple sclerosis. Int J Mol Sci. 2012; 13(10):13227-39. PMC: 3497323. DOI: 10.3390/ijms131013227. View

Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S . MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009; 10(12):1252-9. DOI: 10.1038/ni.1798. View

Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M . Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res. 2011; 93(4):555-62. PMC: 3291086. DOI: 10.1093/cvr/cvr266. View

Vogt L, Schmitz N, Kurrer M, Bauer M, Hinton H, Behnke S . VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest. 2006; 116(10):2817-26. PMC: 1578631. DOI: 10.1172/JCI25673. View

Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R . MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009; 132(Pt 12):3342-52. DOI: 10.1093/brain/awp300. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

10.

Otaegui D, Baranzini S, Armananzas R, Calvo B, Munoz-Culla M, Khankhanian P . Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One. 2009; 4(7):e6309. PMC: 2708922. DOI: 10.1371/journal.pone.0006309. View

11.

Li T, Morgan M, Choksi S, Zhang Y, Kim Y, Liu Z . MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol. 2010; 11(9):799-805. PMC: 2926307. DOI: 10.1038/ni.1918. View

12.

Redis R, Calin S, Yang Y, You M, Calin G . Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther. 2012; 136(2):169-74. PMC: 3855335. DOI: 10.1016/j.pharmthera.2012.08.003. View

13.

Guerau-de-Arellano M, Smith K, Godlewski J, Liu Y, Winger R, Lawler S . Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain. 2011; 134(Pt 12):3578-89. PMC: 3235556. DOI: 10.1093/brain/awr262. View

14.

Polman C, Reingold S, Edan G, Filippi M, Hartung H, Kappos L . Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6):840-6. DOI: 10.1002/ana.20703. View

15.

Xiao C, Srinivasan L, Calado D, Patterson H, Zhang B, Wang J . Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4):405-14. PMC: 2533767. DOI: 10.1038/ni1575. View

16.

Lin S, Fu Y . miR-23 regulation of lamin B1 is crucial for oligodendrocyte development and myelination. Dis Model Mech. 2009; 2(3-4):178-88. PMC: 2650193. DOI: 10.1242/dmm.001065. View

17.

Martinelli-Boneschi F, Fenoglio C, Brambilla P, Sorosina M, Giacalone G, Esposito F . MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett. 2011; 508(1):4-8. DOI: 10.1016/j.neulet.2011.11.006. View

18.

Stys P, Zamponi G, van Minnen J, Geurts J . Will the real multiple sclerosis please stand up?. Nat Rev Neurosci. 2012; 13(7):507-14. DOI: 10.1038/nrn3275. View

19.

Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M . Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One. 2009; 4(10):e7440. PMC: 2757919. DOI: 10.1371/journal.pone.0007440. View

20.

Clemente D, Ortega M, Arenzana F, de Castro F . FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. J Neurosci. 2011; 31(42):14899-909. PMC: 6623557. DOI: 10.1523/JNEUROSCI.1158-11.2011. View